AbCellera Biologics Inc. Royalty Expense
AbCellera Biologics Inc. (ABCL) reported Royalty Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-02-24
- AbCellera Biologics Inc. royalty expense for the quarter ending 2025-03-31 was $0.00.
- AbCellera Biologics Inc. royalty expense for the quarter ending 2024-12-31 was $0.00.
- AbCellera Biologics Inc. royalty expense for the quarter ending 2024-09-30 was $0.00.
- AbCellera Biologics Inc. royalty expense for the quarter ending 2024-06-30 was $0.00.
- AbCellera Biologics Inc. royalty expense for fiscal 2025 was $0.00.
- AbCellera Biologics Inc. royalty expense for fiscal 2024 was $0.00.
- AbCellera Biologics Inc. royalty expense for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AbCellera Biologics Inc. royalty expense for fiscal 2022 was $66.44M, a 45.96% increase from fiscal 2021.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | $1.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $1.55M derived: sum of 3 quarters · filed 2025-02-27 | $16.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $1.55M derived: sum of 2 quarters · filed 2025-02-27 | $16.59M derived: sum of 3 quarters · filed 2025-02-27 | $21.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $16.59M derived: sum of 2 quarters · filed 2025-02-27 | $21.80M derived: sum of 3 quarters · filed 2025-02-27 | $66.44M 10-K · filed 2025-02-27 |
| 2022-09-30 | $15.04M 10-Q · filed 2023-11-02 | $20.25M derived: sum of 2 quarters · filed 2023-11-02 | $64.88M 10-Q · filed 2023-11-02 | $86.78M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.21M 10-Q · filed 2023-08-03 | $49.85M 10-Q · filed 2023-08-03 | $71.74M derived: sum of 3 quarters · filed 2024-02-20 | $71.74M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $44.64M 10-Q · filed 2023-05-04 | $66.53M derived: sum of 2 quarters · filed 2024-02-20 | $66.53M derived: sum of 3 quarters · filed 2024-02-20 | $70.14M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $21.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $21.89M derived: sum of 2 quarters · filed 2024-02-20 | $25.50M derived: sum of 3 quarters · filed 2024-02-20 | $45.52M 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $3.61M derived: sum of 2 quarters · filed 2022-08-09 | $23.62M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $3.61M 10-Q · filed 2022-08-09 | $23.62M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $20.01M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $27.14M 10-K · filed 2023-02-21 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |